Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 3,875 shares of common stock, were issued under the company's 2024 Inducement Plan on August 1, 2025.
The RSUs will vest over four equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.
Praxis Precision Medicines (NASDAQ:PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale, ha assegnato unit脿 azionarie vincolate (RSU) a tre nuovi dipendenti non dirigenti. Le assegnazioni, per un totale di 3.875 azioni ordinarie, sono state emesse nell'ambito del Piano di Incentivi 2024 dell'azienda il 1掳 agosto 2025.
Le RSU matureranno in quattro rate annuali uguali, subordinate alla continuit脿 lavorativa. Questi riconoscimenti sono stati effettuati in conformit脿 alla Regola Nasdaq 5635(c)(4) come premi di incentivo per nuove assunzioni che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (NASDAQ:PRAX), una empresa biofarmac茅utica en etapa cl铆nica enfocada en trastornos del sistema nervioso central, ha otorgado unidades de acciones restringidas (RSU) a tres nuevos empleados no ejecutivos. Las concesiones, que suman 3,875 acciones ordinarias, se emitieron bajo el Plan de Inducci贸n 2024 de la compa帽铆a el 1 de agosto de 2025.
Las RSU se consolidar谩n en cuatro cuotas anuales iguales, condicionadas a la continuidad del empleo. Estas concesiones se hicieron conforme a la Regla de Listado Nasdaq 5635(c)(4) como premios de inducci贸n para nuevas contrataciones que no eran empleados previos de Praxis.
Praxis Precision Medicines (NASDAQ:PRAX)電� 欷戩稊鞁犼步瓿� 歆堩櫂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀, 靹� 氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅鞀惦媹雼�. 齑� 3,875欤�鞚� 氤错喌欤缄皜 2025雲� 8鞗� 1鞚� 須岇偓鞚� 2024雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 氚滍枆霅橃棃鞀惦媹雼�.
搁厂鲍电� 4雲勱皠 毵る厔 霃欖澕頃� 牍勳湪搿� 氩犾姢韺呺悩氅�, 瓿勳啀 瓿犾毄 靸來儨鞚� 瓴届毎鞐� 頃滍暕雼堧嫟. 鞚� 攵�鞐姅 鞚挫爠鞐� Praxis 歆侅洂鞚� 鞎勲媹鞐堧崢 鞁犼窚 毂勳毄鞛愳棎 雽�頃� 鞙犾澑 氤挫儊鞙茧靹� 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Praxis Precision Medicines (NASDAQ:PRAX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les troubles du syst猫me nerveux central, a attribu茅 des unit茅s d'actions restreintes (RSU) 脿 trois nouveaux employ茅s non cadres. Les attributions, totalisant 3 875 actions ordinaires, ont 茅t茅 茅mises dans le cadre du Plan d'Incitation 2024 de la soci茅t茅 le 1er ao没t 2025.
Les RSU seront acquises par quatre versements annuels 茅gaux, sous r茅serve de la poursuite de l'emploi. Ces attributions ont 茅t茅 effectu茅es conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4) en tant que r茅compenses d'incitation pour les nouvelles recrues qui n'茅taient pas auparavant employ茅es par Praxis.
Praxis Precision Medicines (NASDAQ:PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Erkrankungen des zentralen Nervensystems, hat drei neue nicht-exekutive Mitarbeiter mit Restricted Stock Units (RSUs) ausgezeichnet. Die Zuteilungen umfassen insgesamt 3.875 Stammaktien und wurden am 1. August 2025 im Rahmen des Inducement-Plans 2024 des Unternehmens gew盲hrt.
Die RSUs werden in vier gleichen j盲hrlichen Raten anteilig 眉bertragen, abh盲ngig von fortgesetzter Besch盲ftigung. Diese Zuteilungen erfolgten gem盲脽 der Nasdaq-Listenregel 5635(c)(4) als Anreizpr盲mien f眉r neue Mitarbeiter, die zuvor keine Praxis-Angestellten waren.
- None.
- None.
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis鈥� Board of Directors granted restricted stock unit awards covering an aggregate of 3,875 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees鈥� entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals鈥� entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee鈥檚 continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽聽and follow us on聽,听听补苍诲听.
Contacts: Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
What type of stock awards did Praxis Precision Medicines (PRAX) grant to new employees?
How will the RSU awards vest for new Praxis (PRAX) employees?
Why did Praxis (PRAX) issue these stock awards?
What is Praxis Precision Medicines' (PRAX) business focus?
